Company intelligence / Profile preview

Solstice Neurosciences

Malvern, Pennsylvania, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Solstice Neurosciences developed and commercialized Myobloc® (rimabotulinumtoxinB), the only botulinum toxin type B product available for physicians and patients. Myobloc was approved in the US for cervical dystonia and marketed as NeuroBloc in the EU. The company was acquired by US WorldMeds in 2010 for $35.7 million. At acquisition, its lead product was already commercially available.

Therapeutic areas: Neurology
Modalities: Biologics (botulinum toxin type B)
Industry: Biotech

Drug pipeline

1 asset

rimabotulinumtoxinB

Commercial

Indications: Cervical dystonia

Beyond the preview

Go deeper on Solstice Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solstice Neurosciences.

Explore the full profile